
Bruno Dubois

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11499075/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 270-279.	0.8	7,498
2	Movement Disorder Societyâ€sponsored revision of the Unified Parkinson's Disease Rating Scale (MDSâ€UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 2008, 23, 2129-2170.	3.9	4,796
3	MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 2015, 30, 1591-1601.	3.9	4,389
4	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurology, The, 2007, 6, 734-746.	10.2	3,755
5	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
6	Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders, 2007, 22, 1689-1707.	3.9	2,497
7	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
8	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.8	1,863
9	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.8	1,318
10	Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology, The, 2016, 15, 455-532.	10.2	1,242
11	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547.	1.1	1,216
12	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Movement Disorders, 2007, 22, 41-47.	3.9	1,097
13	MDS research criteria for prodromal Parkinson's disease. Movement Disorders, 2015, 30, 1600-1611.	3.9	1,033
14	Apathy and the Functional Anatomy of the Prefrontal Cortex–Basal Ganglia Circuits. Cerebral Cortex, 2006, 16, 916-928.	2.9	1,025
15	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. Movement Disorders, 2007, 22, 2314-2324.	3.9	885
16	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
17	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	10.2	464
18	Amnestic MCI or prodromal Alzheimer's disease?. Lancet Neurology, The, 2004, 3, 246-248.	10.2	459

#	Article	lF	CITATIONS
19	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.8	423
20	Support vector machine-based classification of Alzheimer's disease from whole-brain anatomical MRI. Neuroradiology, 2009, 51, 73-83.	2.2	409
21	A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 95.	6.2	396
22	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurology, The, 2021, 20, 484-496.	10.2	396
23	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Movement Disorders, 2014, 29, 454-462.	3.9	379
24	Implementation of subjective cognitive decline criteria in research studies. Alzheimer's and Dementia, 2017, 13, 296-311.	0.8	375
25	Early and protective microglial activation in Alzheimer's disease: a prospective study using ¹⁸ F-DPA-714 PET imaging. Brain, 2016, 139, 1252-1264.	7.6	365
26	Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. NeuroImage, 2009, 47, 1476-1486.	4.2	354
27	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 58-69.	0.8	352
28	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiology of Aging, 2012, 33, 1203-1214.e2.	3.1	346
29	Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges. Journal of Alzheimer's Disease, 2015, 49, 617-631.	2.6	330
30	Drug development in Alzheimer's disease: the path to 2025. Alzheimer's Research and Therapy, 2016, 8, 39.	6.2	323
31	On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2017, 9, 60.	6.2	316
32	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	10.2	254
33	The Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. Focus (American Psychiatric Publishing), 2013, 11, 96-106.	0.8	241
34	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	2.6	215
35	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature Reviews Neuroscience, 2022, 23, 53-66.	10.2	203
36	Targeting Prodromal Alzheimer Disease With Avagacestat. JAMA Neurology, 2015, 72, 1324.	9.0	179

#	Article	IF	CITATIONS
37	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 474.	0.8	176
38	Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 240-246.	1.9	168
39	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2014, 10, 808-817.	0.8	163
40	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.	0.8	162
41	Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurology, The, 2018, 17, 335-346.	10.2	161
42	Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailty. Frontiers in Aging Neuroscience, 2014, 6, 54.	3.4	155
43	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiology of Aging, 2020, 85, 58-73.	3.1	150
44	Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. Brain, 2013, 136, 3474-3488.	7.6	146
45	Sensitivity to Semantic Cuing: An Index of Episodic Memory Dysfunction in Early Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1999, 13, 38-46.	1.3	142
46	The Amnestic Syndrome of Hippocampal type in Alzheimer's Disease: An MRI Study. Journal of Alzheimer's Disease, 2010, 22, 285-294.	2.6	141
47	Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis. Annals of Neurology, 2008, 64, S81-S92.	5.3	122
48	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 764-775.	0.8	122
49	Similar amyloid-Î ² burden in posterior cortical atrophy and Alzheimer's disease. Brain, 2011, 134, 2036-2043.	7.6	121
50	Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiology of Aging, 2017, 59, 220.e1-220.e9.	3.1	116
51	A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. Alzheimer's and Dementia, 2017, 13, 59-71.	0.8	112
52	Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease. Brain, 2018, 141, 1855-1870.	7.6	111
53	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. Biochemical Pharmacology, 2014, 88, 426-449.	4.4	105
54	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A largeâ€scale international multicenter study. Alzheimer's and Dementia, 2015, 11, 1306-1315.	0.8	104

#	Article	IF	CITATIONS
55	Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1041-1049.	0.8	102
56	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
57	CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1253-1257.	3.1	91
58	Alzheimer's disease biomarkerâ€guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Al² _{1–42} , totalâ€ŧau, phosphorylatedâ€ŧau, NFL, neurogranin, and YKLâ€40. Alzheimer's and Dementia, 2018, 14, 492-501.	0.8	91
59	A Critical Role for the Hippocampus in the Valuation of Imagined Outcomes. PLoS Biology, 2013, 11, e1001684.	5.6	89
60	Two Distinct Amnesic Profiles in Behavioral Variant Frontotemporal Dementia. Biological Psychiatry, 2014, 75, 582-588.	1.3	86
61	Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment. Neurobiology of Aging, 2011, 32, 15-23.	3.1	80
62	Is Hippocampal Volume a Good Marker to Differentiate Alzheimer's Disease from Frontotemporal Dementia?. Journal of Alzheimer's Disease, 2013, 36, 57-66.	2.6	79
63	Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. Scientific Reports, 2017, 7, 11706.	3.3	79
64	Precision pharmacology for Alzheimer's disease. Pharmacological Research, 2018, 130, 331-365.	7.1	79
65	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. Alzheimer's and Dementia, 2018, 14, 1204-1215.	0.8	79
66	Free and Cued Selective Reminding Test – accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: A largeâ€scale biomarkerâ€characterized monocenter cohort study (ClinAD). Alzheimer's and Dementia, 2017, 13, 913-923.	0.8	75
67	Detection of volume loss in hippocampal layers in Alzheimer's disease using 7ÂT MRI: A feasibility study. NeuroImage: Clinical, 2014, 5, 341-348.	2.7	74
68	Early detection of Alzheimer's disease: new diagnostic criteria. Dialogues in Clinical Neuroscience, 2009, 11, 135-139.	3.7	74
69	International Work Group Criteria for the Diagnosis of Alzheimer Disease. Medical Clinics of North America, 2013, 97, 363-368.	2.5	72
70	Alzheimer's Disease Including Focal Presentations. Seminars in Neurology, 2019, 39, 213-226.	1.4	72
71	Temporal Order Memory Assessed during Spatiotemporal Navigation As a Behavioral Cognitive Marker for Differential Alzheimer's Disease Diagnosis. Journal of Neuroscience, 2012, 32, 1942-1952.	3.6	66
72	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. Alzheimer's Research and Therapy, 2017, 9, 27.	6.2	66

#	Article	IF	CITATIONS
73	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Review of Neurotherapeutics, 2015, 15, 83-105.	2.8	64
74	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. Alzheimer's and Dementia, 2021, 17, 1528-1553.	0.8	64
75	Sensitivity and specificity of ventromedial prefrontal cortex tests in behavioral variant frontotemporal dementia. Alzheimer's and Dementia, 2013, 9, S84-94.	0.8	63
76	†̃Prodromal Alzheimer's disease': a more useful concept than mild cognitive impairment?. Current Opinion in Neurology, 2000, 13, 367-369.	3.6	59
77	Social Cognition Deficits: The Key toÂDiscriminate Behavioral Variant Frontotemporal Dementia from Alzheimer's Disease Regardless of Amnesia?. Journal of Alzheimer's Disease, 2016, 49, 1065-1074.	2.6	59
78	How Preserved is Emotion Recognition in Alzheimer Disease Compared With Behavioral Variant Frontotemporal Dementia?. Alzheimer Disease and Associated Disorders, 2015, 29, 154-157.	1.3	59
79	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. Alzheimer's and Dementia, 2017, 13, 454-467.	0.8	58
80	The Emergence of a New Conceptual Framework for Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 1059-1066.	2.6	56
81	The AD-CSF-Index Discriminates Alzheimer's Disease Patients from Healthy Controls: A Validation Study. Journal of Alzheimer's Disease, 2013, 36, 67-77.	2.6	53
82	Clinical and Research Diagnostic Criteria for Alzheimer's Disease. Neuroimaging Clinics of North America, 2012, 22, 23-32.	1.0	51
83	Clinical validation of movement disorder society–recommended diagnostic criteria for Parkinson's disease with dementia. Movement Disorders, 2012, 27, 248-253.	3.9	51
84	Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 153-166.	3.1	49
85	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. Neurobiology of Aging, 2019, 83, 42-53.	3.1	48
86	Frontal lobe neurology and the creative mind. Frontiers in Psychology, 2014, 5, 761.	2.1	47
87	Direct current stimulation over the anterior temporal areas boosts semantic processing in primary progressive aphasia. Annals of Neurology, 2016, 80, 693-707.	5.3	47
88	Determinants of theory of mind performance in Alzheimer's disease: A data-mining study. Cortex, 2017, 88, 8-18.	2.4	47
89	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. Neurochemistry International, 2017, 108, 355-360.	3.8	46
90	Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimer's Research and Therapy, 2017, 9, 67.	6.2	45

#	Article	IF	CITATIONS
91	Association of cerebrospinal fluid αâ€synuclein with total and phosphoâ€tau ₁₈₁ protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2018, 14, 1623-1631.	0.8	45
92	Abolishing the 1â€year rule: How much evidence will be enough?. Movement Disorders, 2016, 31, 1623-1627.	3.9	43
93	Functional Connectivity of Ventral and Dorsal Visual Streams in Posterior Cortical Atrophy. Journal of Alzheimer's Disease, 2016, 51, 1119-1130.	2.6	43
94	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 940-950.	0.8	43
95	Sulcal morphology as a new imaging marker for the diagnosis of early onset Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2932-2939.	3.1	39
96	Twoâ€level diagnostic classification using cerebrospinal fluid YKLâ€40 in Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 993-1003.	0.8	39
97	The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology. Neurobiology of Aging, 2017, 52, 141-152.	3.1	38
98	Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6. Alzheimer's Research and Therapy, 2021, 13, 171.	6.2	37
99	Toward noninvasive brain stimulation 2.0 in Alzheimer's disease. Ageing Research Reviews, 2022, 75, 101555.	10.9	37
100	Parkinson's disease dementia can be easily detected in routine clinical practice. Movement Disorders, 2010, 25, 2769-2776.	3.9	36
101	Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 18.	6.2	36
102	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2017, 59, 1327-1334.	2.6	35
103	Effectiveness of Florbetapir PET Imaging in Changing Patient Management. Dementia and Geriatric Cognitive Disorders, 2017, 44, 129-143.	1.5	35
104	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	6.2	35
105	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S171-S191.	2.6	34
106	Relationships between objectives sleep parameters and brain amyloid load in subjects at risk for Alzheimer's disease: the INSIGHT-preAD Study. Sleep, 2019, 42, .	1.1	32
107	Disrupted white matter structural networks in healthy older adult APOE ε4 carriers – An international multicenter DTI study. Neuroscience, 2017, 357, 119-133.	2.3	31
108	Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. Journal of Neurology, 2014, 261, 1234-1243.	3.6	30

#	Article	IF	CITATIONS
109	Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid-β Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. Radiology, 2019, 290, 167-176.	7.3	30
110	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. Neurobiology of Aging, 2020, 90, 43-59.	3.1	30
111	Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease with an implantable ultrasound device. Alzheimer's Research and Therapy, 2022, 14, 40.	6.2	30
112	Frontal presentation of Alzheimer's disease: A series of patients with biological evidence by CSF biomarkers. Dementia E Neuropsychologia, 2013, 7, 66-74.	0.8	29
113	Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. Journal of Alzheimer's Disease, 2015, 48, 793-804.	2.6	28
114	Why do patients with neurodegenerative frontal syndrome fail to answer: â€~In what way are an orange and a banana alike?'. Brain, 2015, 138, 456-471.	7.6	28
115	Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada. Canadian Journal of Neurological Sciences, 2016, 43, 503-512.	0.5	27
116	Cognitive and behavioural inhibition deficits in neurodegenerative dementias. Cortex, 2020, 131, 265-283.	2.4	27
117	Clinical Investigations in Primary Care. Frontiers of Neurology and Neuroscience, 2009, 24, 1-11.	2.8	26
118	Fully Automated Atlas-Based Hippocampus Volumetry for Clinical Routine: Validation in Subjects with Mild Cognitive Impairment from the ADNI Cohort. Journal of Alzheimer's Disease, 2015, 46, 199-209.	2.6	25
119	Brain Al ² load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. Alzheimer's and Dementia, 2019, 15, 1274-1285.	0.8	25
120	Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimer's Research and Therapy, 2019, 11, 15.	6.2	24
121	Distinct brain perfusion pattern associated with CSF biomarkers profile in primary progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 695-698.	1.9	23
122	World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. International Journal of Psychiatry in Clinical Practice, 2015, 19, 2-7.	2.4	23
123	Neural correlates of episodic memory in the Memento cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 224-233.	3.7	23
124	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. Alzheimer's Research and Therapy, 2020, 12, 147.	6.2	23
125	Primary Progressive Aphasia Associated With <i>GRN</i> Mutations. Neurology, 2021, 97, e88-e102.	1.1	23
126	Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 589-593.	6.4	22

#	Article	IF	CITATIONS
127	Low Prevalence and Clinical Effect of Vascular Risk Factors in Early-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 1045-1054.	2.6	22
128	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.8	22
129	Revised research diagnostic criteria for Alzheimer's disease. Lancet Neurology, The, 2008, 7, 668-670.	10.2	21
130	Neuroimaging in dementias. Current Opinion in Psychiatry, 2012, 25, 473-479.	6.3	21
131	Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkers. NeuroImage: Clinical, 2018, 20, 1018-1025.	2.7	21
132	InÂvivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. Neurobiology of Aging, 2020, 93, 98-108.	3.1	21
133	Judgments about moral responsibility and determinism in patients with behavioural variant of frontotemporal dementia: Still compatibilists. Consciousness and Cognition, 2012, 21, 851-864.	1.5	20
134	Amyloidosis and neurodegeneration result in distinct structural connectivity patterns in mild cognitive impairment. Neurobiology of Aging, 2017, 55, 177-189.	3.1	20
135	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology, 2020, 94, e30-e41.	1.1	20
136	European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. European Journal of Neurology, 2021, 28, 2147-2155.	3.3	20
137	Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 51, 867-873.	2.6	19
138	No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints. NeuroImage: Clinical, 2018, 17, 435-443.	2.7	19
139	Accuracy of MRI Classification Algorithms in a Tertiary Memory Center Clinical Routine Cohort. Journal of Alzheimer's Disease, 2020, 74, 1157-1166.	2.6	19
140	Biomarker counseling, disclosure of diagnosis and followâ€up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. International Journal of Geriatric Psychiatry, 2021, 36, 324-333.	2.7	19
141	Biological markers of Alzheimer?s disease. Arquivos De Neuro-Psiquiatria, 2014, 72, 227-231.	0.8	18
142	Influence of Lewy Pathology on Alzheimer's Disease Phenotype: AÂRetrospective Clinico-Pathological Study. Journal of Alzheimer's Disease, 2018, 63, 1317-1323.	2.6	18
143	Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD. Alzheimer's Research and Therapy, 2020, 12, 129.	6.2	18
144	Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers. Neurobiology of Aging, 2020, 96, 22-32.	3.1	18

#	Article	IF	CITATIONS
145	Radiological classification of dementia from anatomical MRI assisted by machine learning-derived maps. Journal of Neuroradiology, 2021, 48, 412-418.	1.1	18
146	A machine learning approach to screen for preclinical Alzheimer's disease. Neurobiology of Aging, 2021, 105, 205-216.	3.1	18
147	AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. Alzheimer's and Dementia, 2011, 7, e109-17.	0.8	17
148	So Close Yet So Far: Executive Contribution to Memory Processing in Behavioral Variant Frontotemporal Dementia. Journal of Alzheimer's Disease, 2016, 54, 1005-1014.	2.6	17
149	Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. Frontiers in Aging Neuroscience, 2021, 13, 697234.	3.4	17
150	Which Episodic Memory Performance is Associated with Alzheimer's Disease Biomarkers in Elderly Cognitive Complainers? Evidence from a Longitudinal Observational Study with Four Episodic Memory Tests (Insight-PreAD). Journal of Alzheimer's Disease, 2019, 70, 811-824.	2.6	16
151	How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years. BMJ Open, 2019, 9, e029663.	1.9	16
152	β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. Alzheimer's Research and Therapy, 2020, 12, 130.	6.2	16
153	Does amnesia specifically predict Alzheimer's pathology? AÂneuropathological study. Neurobiology of Aging, 2020, 95, 123-130.	3.1	15
154	The utility of the new research diagnostic criteria for Alzheimer's disease. International Psychogeriatrics, 2013, 25, 175-177.	1.0	14
155	Language boosting by transcranial stimulation in progressive supranuclear palsy. Neurology, 2019, 93, e537-e547.	1.1	14
156	Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasias. Neurology, 2018, 90, e1057-e1065.	1.1	13
157	MiRNA-15b and miRNA-125b are associated with regional Aβ-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. Translational Psychiatry, 2021, 11, 78.	4.8	13
158	Intepirdine as adjunctive therapy to donepezil for mildâ€ŧoâ€moderate Alzheimer's disease: A randomized, placeboâ€controlled, phase 3 clinical trial (MINDSET). Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12136.	3.7	12
159	A Reliable and Rapid Language Tool for the Diagnosis, Classification, and Follow-Up of Primary Progressive Aphasia Variants. Frontiers in Neurology, 2020, 11, 571657.	2.4	11
160	A mosquito bites and a butterfly flies: A specific response type of frontal patients in a similarity task. Neuropsychologia, 2018, 117, 371-378.	1.6	10
161	Moral Emotions in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2019, 69, 887-896.	2.6	10
162	Plasma βâ€secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. Alzheimer's and Dementia, 2021, 17, 629-640.	0.8	10

#	Article	IF	CITATIONS
163	Effect of Six Months of Treatment with V0191 in Patients with Suspected Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 527-535.	2.6	9
164	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 455-461.	0.8	9
165	Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 553-562.	3.7	8
166	Cognition, behavior and the frontal lobes. International Psychogeriatrics, 2004, 16, 379-387.	1.0	7
167	New lexicon and criteria for the diagnosis of Alzheimer's disease – Authors' reply. Lancet Neurology, The, 2011, 10, 300-301.	10.2	7
168	Behavioral variant frontotemporal dementia patients do not succumb to the Allais paradox. Frontiers in Neuroscience, 2014, 8, 287.	2.8	7
169	Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. Movement Disorders, 2014, 29, 1252-1257.	3.9	7
170	Altered ageâ€linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHTâ€preAD study) with high brain amyloid load. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12046.	3.7	7
171	Relevance of the Evaluation Criteria Used in Clinical Trials for Alzheimer's Disease. Therapie, 2009, 64, 145-148.	1.0	5
172	Parietal Involvement in the Semantic Variant of Primary Progressive Aphasia with Alzheimer's Disease Cerebrospinal Fluid Profile. Journal of Alzheimer's Disease, 2018, 66, 271-280.	2.6	5
173	Association of plasma Aβ40/Aβ42 ratio and brain Aβ accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. Neurobiology of Aging, 2021, 107, 57-69.	3.1	5
174	Magnetic resonance imagingâ€based hippocampus volume for prediction of dementia in mild cognitive impairment: Why does the measurement method matter so little?. Alzheimer's and Dementia, 2018, 14, 976-978.	0.8	4
175	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. Neurobiology of Aging, 2020, 88, 83-90.	3.1	4
176	Overview of dominantly inherited AD and topâ€line DIANâ€TU results of solanezumab and gantenerumab. Alzheimer's and Dementia, 2020, 16, e041129.	0.8	4
177	Are PSP patients included in clinical trials representative of the general PSP population?. Parkinsonism and Related Disorders, 2019, 66, 202-206.	2.2	3
178	Does surface dyslexia/dysgraphia relate to semantic deficits in the semantic variant of primary progressive aphasia?. Neuropsychologia, 2019, 135, 107241.	1.6	3
179	Solanezumab inâ€depth outcomes. Alzheimer's and Dementia, 2020, 16, e038028.	0.8	3
180	Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis. Frontiers in Aging Neuroscience, 2021, 13, 748198.	3.4	3

#	Article	IF	CITATIONS
181	Clinical diagnosis of Alzheimer's disease: Recommendations of the International Working Group (IWG). Alzheimer's and Dementia, 2021, 17, .	0.8	3
182	Alzheimer's Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports. Journal of Alzheimer's Disease, 2017, 60, 577-583.	2.6	2
183	COGEVIS: A New Scale to Evaluate Cognition in Patients with Visual Deficiency. Behavioural Neurology, 2018, 2018, 1-7.	2.1	2
184	Gantenerumab inâ \in depth outcomes. Alzheimer's and Dementia, 2020, 16, e038049.	0.8	2
185	Alzheimer's disease brain atrophy subtypes are associated with incident dementia in subjective complaint and mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e039861.	0.8	2
186	Aging and sex impact plasma NFL and tâ€Tau trajectories in individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e041792.	0.8	2
187	Biomarkers for the Early Stages of Clinical Development in Alzheimer's Disease. Therapie, 2010, 65, 285-290.	1.0	1
188	P3â€218: NOVEL ALZHEIMER'S DISEASE BIOMARKERâ€GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VA OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: Aβ _{1â€42} , TOTALâ€TAU, PHOSPHORYLATEDâ€TAU, NFL, NEUROGRANIN, AND YKLâ€40. Alzheimer's and Dementia, 2018, 14, P1154.	LUE 0.8	1
189	P1â€313: THE EATING BEHAVIOR INVENTORY (EBI): A 30â€ITEM CLINICAL TOOL TO DISTINGUISH FRONTOTEMPO DEMENTIA FROM BIPOLAR DISORDER. Alzheimer's and Dementia, 2018, 14, P411.	IRAL 0.8	1
190	EEG: A valuable tool to screen for neurodegeneration in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e039696.	0.8	1
191	Recommendations of the International Working Group for the clinical diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	1
192	S2-02-01: Concepts of Preclinical Dementias. , 2011, 7, S280-S280.		0
193	Subjective cognitive complaint. , 0, , 6-12.		0
194	Ask The Experts: New diagnostic criteria for Alzheimer's disease. Neurodegenerative Disease Management, 2012, 2, 153-157.	2.2	0
195	[P1–301]: THE MINI EATING BEHAVIOR INVENTORY (MINI EBI): A 10â€ITEM CLINICAL TOOL FOR THE EARLY DIAGNOSIS OF FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P368.	0.8	0
196	[P2–412]: A FUNCTIONAL RESTING STATE STUDY OF BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN ASYMPTOMATIC ATâ€RISK INDIVIDUALS FOR AD: THE INSIGHTâ€PREAD STUDY. Alzheimer's and Dementia, 2017, 13, P790.	0.8	0
197	[ICâ€Pâ€152]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTINGâ€STATE EEG FUNCTIONAL CONNECTI IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHTâ€PRE AD STUDY. Alzheimer's and Dementia, 2017, 13, P114.	VITY 0.8	0
198	[P1–388]: DIFFERENT STRUCTURAL CONNECTIVITY PATTERNS IN MILD COGNITIVE IMPAIRMENT STRATIFIED BY AMYLOID AND NEURODEGENERATION BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P414.	0.8	0

#	Article	IF	CITATIONS
199	[P1–438]: SPONTANEOUS LOWâ€FREQUENCY BOLD SIGNAL FLUCTUATIONS IN OLDER SUBJECTIVE MEMORY COMPLAINERS WITH OR WITHOUT BRAIN AMYLOIDOSIS: THE INSIGHTâ€PREâ€AD STUDY. Alzheimer's and Dementia, 2017, 13, P450.	0.8	0
200	[P1–441]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTING TATE EEG FUNCTIONAL CONNECTIVI IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHTâ€PREâ€AD STUDY. Alzheimer's and Dementia, 2017, 13, P451.	TY 0.8	0
201	[P2–028]: EFFECT OF CHOLINESTERASE INHIBITORS ON BRAIN CHOLINERGIC STRUCTURES. Alzheimer's and Dementia, 2017, 13, P615.	0.8	0
202	[P4–236]: COMPARISON OF BRAIN MORPHOLOGY BETWEEN TWO DATABASES OF ELDERLY COGNITIVELY INTACT INDIVIDUALS FOR THE VALIDATION OF HIPPOCAMPAL VOLUME NORMATIVE DATA IN THE FRENCH INSIGHTâ€PRE AD COHORT. Alzheimer's and Dementia, 2017, 13, P1364.	0.8	0
203	P4â€072: INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL. Alzheimer's and Dementia, 2018, 14, P1461.	0.8	0
204	P1â€627: AMYLOID BURDEN IMPACTS EVERYDAY FUNCTIONING INDEPENDENT OF COGNITION AND AWARENESS IN SUBJECTIVE COGNITIVE DECLINE: FINDINGS FROM THE INSIGHT PREâ€AD COHORT. Alzheimer's and Dementia, 2018, 14, P581.	5 0.8	0
205	P3â€411: CLINICAL SIGNIFICANCE OF INâ€VIVO STAGING OF REGIONAL AMYLOID DEPOSITION IN SUBJECTIVE MEMORY COMPLAINERS. Alzheimer's and Dementia, 2018, 14, P1262.	0.8	0
206	P3â€⊋79: COGNITION AND LOW VISION: COGEVIS. Alzheimer's and Dementia, 2018, 14, P1185.	0.8	0
207	P2â€237: ASSOCIATION OF CSF ALPHAâ€SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTIONS STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P762.	CAL 0.8	0
208	O4â€07â€04: INCREASED RESILIENCE TO ALZHEIMER'S DISEASE PATHOPHYSIOLOGY IN MEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO WOMEN. Alzheimer's and Dementia, 2018, 14, P1419.	0.8	0
209	O3â€09â€02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOIDâ€PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P1036.	0.8	0
210	P4â€186: INNOVATIVE BIOMARKERâ€GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEAS DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1510.	E _{0.8}	0
211	P2â€⊋46: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKLâ€40 CONCENTRATIONS IN AMYLOIDâ€PET PO INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P767.	SITIVE 0.8	0
212	P2â€249: CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P768.	0.8	0
213	P2â€⊋77: CORTICAL SULCI WIDTH AND INCIDENT DEMENTIA IN OUTPATIENTS ATTENDING FRENCH MEMORY CLINICS: THE MEMENTO COHORT. Alzheimer's and Dementia, 2018, 14, P784.	0.8	Ο
214	P4â€088: EVOLUTION OF THE AWARENESS OF COGNITIVE DECLINE INDEX OVER 24 MONTHS IN PRECLINICAL ALZHEIMER'S DISEASE IS ASSOCIATED TO BASELINE BRAIN AMYLOID LOAD. Alzheimer's and Dementia, 2018, 14, P1469.	0.8	0
215	Reduced awareness of cognitive decline is associated with brain amyloid load in asymptomatic elderly individuals at risk for AD: A longitudinal study. Alzheimer's and Dementia, 2020, 16, e037138.	0.8	Ο
216	A specific pattern of memory errors in asymptomatic atâ€risk for AD. Alzheimer's and Dementia, 2020, 16, e037385.	0.8	0

#	Article	IF	CITATIONS
217	Inâ€vivo characterization of progressive amnestic syndrome due to suspected neurodegenerative nonâ€Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e039587.	0.8	0
218	Association of plasma YKLâ€40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. Alzheimer's and Dementia, 2020, 16, e041753.	0.8	0
219	Pathways involved in the relationship between resilience and cognitive function: The Memento cohort. Alzheimer's and Dementia, 2020, 16, e042674.	0.8	0
220	Predicting factors of cognitive progression in preclinical AD: A fiveâ€year followâ€up of the insightâ€study. Alzheimer's and Dementia, 2020, 16, e042896.	0.8	0
221	Multimodal screening for neurodegeneration in preclinical Alzheimer's disease using EEC, APOE4 genotype, neuropsychological and MRI data. Alzheimer's and Dementia, 2020, 16, e044027.	0.8	0
222	Current status and quantitative results of the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, e044711.	0.8	0
223	Cortical microstructural changes and amyloid beta burden in cognitively normal subjective memory complainers. Alzheimer's and Dementia, 2020, 16, e046014.	0.8	0
224	Sex differences in cortical microstructural changes in asymptomatic individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046105.	0.8	0
225	Impact of the IWG/Dubois Criteria for Alzheimer's Disease in Imaging Studies. , 2014, , 309-322.		0
226	Que penser de l'approche médicamenteuse préventive de la maladie d'Alzheimer ?. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 679-690.	0.0	0
227	IncRNAs as a novel source of diagnostic applications for early Alzheimer's disease and other dementia types. Alzheimer's and Dementia, 2020, 16, e039788.	0.8	0
228	Enlightening behavioral disturbances in myotonic dystrophy type 1 through neuropsychology and imaging correlations: Insights from the frontal and temporal lobe functions. Alzheimer's and Dementia, 2020, 16, e043114.	0.8	0
229	Impact of the New Conceptual Framework of Alzheimer's Disease in Imaging Studies. , 2021, , 427-451.		0
230	Subtle postoperative cognitive disorder in preclinical Alzheimer's disease. Experimental Gerontology, 2022, 161, 111715.	2.8	0
231	Why don't Alzheimer's disease patients know that they forget?. Alzheimer's and Dementia, 2021, 17, .	0.8	0
232	Education and brain amyloid load act on temporal lobe function in individual with subjective memory complaint: An EEGâ€fMRI study. Alzheimer's and Dementia, 2021, 17, .	0.8	0